Searchable abstracts of presentations at key conferences in endocrinology

ea0035oc2.2 | Adrenal clinical | ECE2014

Constitutive activation of PRKACA in adrenal Cushing’s syndrome

Beuschlein Felix , Fassnacht Martin , Assie Guilaume , Calebiro Davide , Stratakis Constantine A. , Osswald Andrea , Ronchi Cristina L. , Wieland Thomas , Sbiera Silviu , Faucz Fabio R. , Schaak Katrin , Schmittfull Anett , Kisker Caroline , Diener Susanne , Meitinger Thomas , Lohse Martin J. , Reincke Martin , Bertherat Jerome , Strom Tim M. , Allolio Bruno

Background and Methods: Corticotropin-independent Cushing’s syndrome is caused by tumors or hyperplasia of the adrenal cortex. The molecular pathogenesis of cortisol producing adrenal adenomas is not well understood. Therefore, exome sequencing was performed in 10 cortisol-producing adenomas and recurrent mutations in candidate genes were evaluated in additional 171 patients with adrenocortical tumors. In addition, genome-wide copy number analysis was performed in 35 pati...

ea0035oc2.3 | Adrenal clinical | ECE2014

Prognostic value of DNA methylation in adrenocortical carcinomas: an ENSAT study

Assie Guillaume , Jouinot Anne , Libe Rossella , Barreau Olivia , Papathomas Thomas , Hamzaoui Nadim , Sbiera Silviu , Ronchi Christina , Kroiss Matthias , Waldmann Jens , Quinkler Marcus , Beuschlein Felix , Mannelli Massimo , Luconi Michaela , Mantero Franco , Groussin Lionel , Baudin Eric , de Krijger Ronald , Fassnacht Martin , Bertherat Jerome

Background: The prognosis of adrenocortical carcinomas (ACCs) is heterogeneous. Genome-wide methylation analysis of tumor DNA identified a sub-group of ACCs from the French COMETE network with CpG island hypermethylation evoking a CpG island methylator phenotype (CIMP). These ACCs are associated with a poorer prognosis (Barreau, JCEM 2013).The aim was to validate the prognostic value of CIMP in a large multicentric independent cohort from ENSAT (European...

ea0070oc1.6 | Adrenal and Cardiovascular Endocrinology | ECE2020

Modified GRAS score for prognostic classification of adrenocortical carcinoma: an ENSAT multicentre study

Elhassan Yasir , Altieri Barbara , Berhane Sarah , Cook Harriet , Bertherat Jerome , Fragoso Maria , Kastelan Darko , Terzolo Massimo , Calabrese Anna , Berruti Alfredo , Cosentini Deborah , Laganà Marta , Loli Paola , Baudin Eric , Haak Harm , Canu Letizia , Haissaguerre Magalie , Kimpel Otilia , Deeks Jon , Arlt Wiebke , Libé Rossella , Fassnacht Martin , Ronchi Cristina

Background: Adrenocortical carcinoma (ACC) has an aggressive but heterogenous behaviour. ENSAT stage and Ki67 proliferation index are used to predict clinical outcome but are limited in distinguishing patients with best outcome. We aimed to validate the prognostic role of clinical and histopathological parameters alone or combined by applying a previously proposed points-based score (mGRAS, Lippert JCEM 2018) to a large multicentre cohort of ACC patients.<p class="abstext"...

ea0070oc7.1 | Endocrine-related Cancer | ECE2020

Is Carney complex a breast cancer predisposing syndrome? prospective study of 50 women

Vaduva Patricia , Espiard Stéphanie , Jouinot Anne , Vantyghem Marie-Christine , Assié Guillaume , Catherine Cardot-Bauters , Raverot Gerald , Sylvie Hieronimus , Francoise Archambeaud , Hervé Lefebvre , Laure Nunes , Tabarin Antoine , Anne Lienhardt , Groussin Lionel , Guignat Laurence , Fideline Bonnet , North Marie-Odile , Bertherat Jerome

Introduction: Carney Complex (CNC) is a rare genetic syndrome, with multiple endocrine and non-endocrine neoplasia, mostly due to inactivating mutations of the PRKAR1A gene. CNC has a wide spectrum of manifestations : most frequently skin lesions, cardiac myxomas and primary pigmented nodular adrenocortical dysplasia (PPNAD), but also thyroid nodules, schwannomas, breast tumors (mainly myxoid fibroadenomas and ductal adenomas)… The present study was designed to ...

ea0032oc4.3 | Adrenal | ECE2013

Prognostic factors of advanced unresectable by stage III and IV ENS@T adrenocortical carcinomas (ACC)

Libe Rossella , Borget Isabelle , Ronchi Cristina , Terzolo Massimo , Haaf Michaela , Laino Federica , Kherkhof Thomas , Corsini Elisa , Tabarin Antoine , Chabre Olivier , De la Fouchardiere Christelle , Niccoli Patricia , Caron Philippe , Mannelli Massimo , Haak Harm , Beuchlein Felix , Bertherat Jerome , Berruti Alfredo , Fassnacht Martin , Baudin Eric

Introduction: The prognosis of stages III–IV ACC patients is dismal. The 5-year survival of stage IV ACC ranges between 0 and 13% and no prognostic study has focused on stage III, yet. Several reports suggest a greater heterogeneity of advanced ACC prognosis that initially thought.Aim: The primary objective of our study was to analyse the prognostic factors of overall survival of the subgroup of advanced unresectable stage III–IV ACC patients c...

ea0032p846 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Characteristics of patients with pituitary gigantism: results of an international study

Rostomyan Liliya , Daly Adrian F. , Tichomirowa Maria , Naves Luciana A. , Shah Nalini , Chanson Philippe , Zacharieva Sabina , Stratskis Constantine A , Neggers Sebastian , Holdaway Ian , Stalla Gunter K. , Pronin Vyacheslav , Maiter Dominique , Bertherat Jerome , Colao Annamaria , Ilovaiskaya Irena , Ferone Diego , Zacharin Margaret , Salvatori Roberto , Beckers Albert

Aim: To analyse a large series of patients with pituitary gigantism.Materials and methods: We included in this multicentre study 158 patients (129 males) with pituitary adenoma (PA) or hyperplasia and current/previous abnormal, excessively rapid growth velocity for age or a final height greater than 2 SD above normal for their population. Data of patients were systematically recorded in case report forms.Results: The...

ea0029oc7.1 | Adrenal Clinical | ICEECE2012

Progression-free survival without treatment of malignant pheochromocytoma and paraganglioma at one year

Hescot S. , Leboulleux S. , Amar L. , Borget I. , Vezzosi D. , Libe R. , Niccoli P. , Borson-Chazot F. , Do Cao C. , Tabarin A. , de la Fouchardiere C. , Raingeard I. , Chougnet C. , Gimenez-Roqueplo A. , Young J. , Bertherat J. , Wemeau J. , Bertagna X. , Schlumberger M. , Plouin P. , Baudin E.

Pheochromocytoma and paraganglioma are defined as malignant by the occurence of metastasis in extra paraganglionic sites. The natural evolution of these tumors remains unknown.The aim of our retrospective study was to define the progression-free survival (PFS) of untreated Malignant Pheochromocytoma and Paraganglioma (MPP) at 12 months (12 m-PFS) and to look for prognostic markers of 12 m-PFS. We analyzed clinical parameters of patients followed within 8...

ea0029p782 | Endocrine tumours and neoplasia | ICEECE2012

Urinary steroid profiling demonstrates induction of CYP3A4 and inhibition of 5alpha-reductase by mitotane treatment for adrenocortical carcinoma

Taylor A. , Chortis V. , Schneider P. , Tomlinson J. , Hughes B. , Smith D. , Libe R. , Allolio B. , Bertagna X. , Bertherat J. , Beuschlein F. , Fassnacht M. , Mannelli M. , Mantero F. , Opocher G. , Porfiri E. , Quinkler M. , Terzolo M. , Shackelton C. , Stewart P. , Hanher S. , Arlt W.

Mitotane (o,p’DDD) is commonly used for the treatment of adrenocortical carcinoma (ACC), both for advanced disease and in the adjuvant setting. Mitotane induces adrenal insufficiency but specific effects on steroidogenic enzymes are unknown.We investigated 24-h urinary steroid metabolite excretion in ACC patients on adjuvant mitotane (AD) or mitotane for metastatic disease (MET). We compared samples collected before mitotane treatment (BEFORE; MET <...

ea0026p70 | Endocrine tumours and neoplasia | ECE2011

First prognostic analysis of stage III adrenocartical carcinoma patients after complete resection: a retrospective French Multicentric Study from the INCA-COMETE network

Do Cao C , Leboulleux S , Borget I , Bertherat J , De la Fouchardiere C , Hecart A C , Caron P , Tabarin A , Niccoli P , Rohmer V , Drui D , Schillo F , Raingeard I , Young J , Ghuzlan A , Borson-Chazot F , Bertagna X , Pattou F , Wemeau J L , Francis Z , Libe R , Aubert S , Baudin E

Objective: To assess outcome of stage III–ENSAT adrenocortical carcinoma (ACC) patients after complete macroscopic resection and prognostic factors for disease-free survival (DFS) and overall survival (OS).Methods: A retrospective review of 68 stage III ACC patients treated surgically between 1994 and 2009 in the French COMETE network was performed. Characteristics of patients were reviewed by a single investigator as well as the Weiss score by expe...

ea0056oc7.4 | Genomic and clinical aspects of endocrine tumours | ECE2018

Germline mutations in the mitochondrial 2-oxoglutarate/malate carrier (SLC25A11) gene confer predisposition to metastatic paragangliomas

Buffet Alexandre , Morin Aurelie , Castro-Vega Luis-Jaime , Habarou Florence , Lussey-Lepoutre Charlotte , Letouze Eric , Lefebvre Herve , Guilhem Isabelle , Haissaguerre Magalie , Raingeard Isabelle , Padilla-Girola Mathilde , Tran Thi , Tchara Lucien , Bertherat Jerome , Amar Laurence , Ottolenghi Chris , Burnichon Nelly , Gimenez-Roqueplo Anne-Paule , Favier Judith

Integrative genomics studies of paragangliomas (PGL) have shown that PGL susceptibility genes are the main drivers of tumorigenesis. Comprehensive genetic analyses have identified germline SDHB and, to a lesser extent, FH gene mutations, as predominant causes of metastatic PGL. However, some suspicious cases remain unexplained. We performed whole-exome sequencing of a paraganglioma exhibiting an SDHx-like molecular profile in the absence of SDHx<...